最近研究人员称,一种新的辅助疗法将有助于改善非胰岛素依赖性糖尿病(Ⅱ型糖尿病)患者的血糖控制。多伦多地区高级调查员Robert Josse说,这种新的抗糖尿病药物与其它疗法联合使用时,将明显降低糖基化血红蛋白(HbAlc-血糖控制的一项指标)的记数和餐后血糖浓度。这里所说的药物是阿卡糖(acarbose),一种针对肠内消化糖类的刷状缘酶的竞争性酶抑制 Researchers said a new adjuvant therapy will help improve glycemic control in patients with non-insulin-dependent diabetes mellitus (type 2 diabetes). Robert Josse, a Toronto-based senior investigator, said the new antidiabetic drug, when used in combination with other therapies, will significantly reduce the glycosylated hemoglobin (HbAlc, an indicator of glycemic control) and postprandial blood glucose levels. The drug here is acarbose, a competitive enzyme that inhibits the brush border enzyme of the intestinal digestive saccharide